U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07722286) titled 'Relapse and Functional Outcomes in Anti-LGI1 Encephalitis' on Nov. 29, 2025.
Brief Summary: This study focuses on a rare brain disease called anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis. In this condition, the body's immune system mistakenly attacks a protein in the brain, which can cause problems with memory, thinking, behavior, and seizures. While most patients get better with initial treatments, some continue to have long-term symptoms or experience a return of the disease (called a "relapse") months or years later. The goal of this study is to understand how often these relapses and long-term problems happen and t...